Appendix 4C for the September 2016 quarter

31 October 2016

The Manager
Company Announcements Office
ASX Limited
20 Bridge St

Dear Sir


Invion Limited (ASX:IVX) is pleased to lodge its Appendix 4C for the quarter ending 30 September 2016.

The Company held cash reserves of $0.664 million at the end of September, with cash outflows during the quarter at $0.232 million. As reported in previous quarters, operating cash outflows have been reduced reflecting lower capital-intensive activity following the completion of major R&D program milestones.

These milestones include the completion of two phase II clinical trials for the company’s lead drug asset – INV102(nadolol) – being a phase II study of nadolol in patients with chronic bronchitis, and a phase II study of nadolol in patients with mild asthma. The Company is driven to realise value from its assets via a commercial transaction following the successful completion of its major R&D milestones. The activity of the Company therefore has been directed towards business development, and the partnering (via sale or out-licence) of one or all of its assets.

An Appendix 4C accompanies this announcement.

For and on behalf of the Board of Invion Limited

Company Secretary and Head of Operations


Posted in ASX Releases